HAYA Therapeutics develops modified antisense oligonucleotides (ASOs) to target and inhibit long non-coding RNAs (lncRNAs) associated with heart failure and other chronic diseases. By focusing on dark genome-derived regulatory RNAs, the company aims to prevent and reverse disease processes in diseased tissues and cells.
Funding
$37.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ELFounders
Product
Problem
Heart failure resulting from myocardial fibrosis is a leading cause of death, representing a significant unmet medical need. Current treatments do not directly address the underlying fibrotic mechanisms in the heart and other tissues. There is a need for novel therapeutics that can specifically target and reverse fibrosis to prevent disease progression.
Solution
HAYA Therapeutics is developing a new class of anti-fibrotic therapies by targeting long non-coding RNAs (lncRNAs). Their lead candidate is designed to inhibit Wisper, a master regulator of fibrosis in the heart. By selectively targeting lncRNAs within diseased tissues and cells, HAYA's approach aims to prevent and reverse disease processes. The company utilizes modified antisense oligonucleotides (ASOs) to precisely target and inhibit proprietary lncRNAs, offering a potential solution for myocardial fibrosis and other chronic fibrotic diseases. HAYA's target discovery engine identifies and validates novel lncRNA anti-fibrotic targets across multiple tissues and indications, expanding the therapeutic pipeline.
Target Audience
The primary target audience includes patients with myocardial fibrosis and heart failure, as well as individuals at risk of developing fibrotic diseases in other organs.
Features
- Modified antisense oligonucleotides (ASOs) designed for enhanced stability and targeted delivery
- Proprietary lncRNA targets identified using advanced genomic and transcriptomic analysis
- Target discovery engine for identifying novel anti-fibrotic targets in various tissues
- Preclinical validation studies demonstrating efficacy in relevant disease models
- Potential for combination therapies with existing heart failure treatments